We are pleased to announce that FCTDI has been issued a 5-yr R01 entitled “AI-driven discovery of in vivo chemical probes for understudied targets for the treatment of Alzheimer’s disease and related disorders (ADRD)” from the National Institute of Aging (R01AG098139-01).
FCTDI issued a 5-yr R01 from the National Institute of Aging
February 26, 2026